Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis

Journal of the American Society of Nephrology

Volumn 7, Issue 2, 1996, Pages 247-253

  Welch, Paul G ^a   Fattom, Ali ^b   Moore, Jack ^a   Schneerson, Rachel ^c   Shiloach, Joseph ^d   Bryla, Dolores A ^c   Li, Xiuru ^b   Robbins, John B ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIVAX Biologies Inc   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antibody response; Conjugate vaccine; End stage renal disease; Staphylococcus aureus vaccine

Indexed keywords

PSEUDOMONAS VACCINE; STAPHYLOCOCCUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0029878247     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Arbeit RD, Karakawa WW, Van WF, Robbins JB: Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 1984;2:85-91.
2. Boutonnier A, Nato F, Bouvet A, et al.: Direct testing of blood cultures for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol 1989;27:989-994.
3. Cisse MF, Sow AI, Samb A: Infections neonatales bacteriennes en zone tropicale. Med Trop 1991;51:429-443.
4. Cluff LE, Reynolds RC, Page DL, Breckenridge JL: Staphylococcal bacteremia and altered host resistance. Ann Intern Med 1968;69:859-871.
5. Dobkin JF, Miller MH, Steigbigel NH: Septicemia in patients on chronic hemodialysis. Ann Intern Med 1978; 88:28-33.
6. Finland M, Peterson O, Strauss L: Staphylococcic pneumonia occurring during an epidemic of influenza. Arch Intern Med 1942;70:183-205.
7. Fournier JM, Bouvert A, Boutonnier A, et al.: Predominance of capsular polysaccharide type 5 among oxacillin-resistant Staphylococcus aureus. J Clin Microbiol 1987; 25:1932-1933.
8. Geiseler PJ, Nelson KE, Levin S, Reddi KT, Moses VK: Community-acquired purulent meningitis: A review of 1,316 cases during the antibiotic era, 1954-1976. Rev Infect Dis 1980;2:725-745.
9. Louria DB, Blumenfield HL, Ellis JT, Kilbourne ED, Rodgers DE: Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959;38:213-265.
10. Ludlam HA, Young AE, Berry AJ, Philips I: The prevention of infection with Staphylococcus aureus in continuous peritoneal dialysis. J Hosp Infect 1989;14:293-301.
11. McGowan JE, Barnes MW, Finland M: Bacteremia at Boston City Hospital; occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 1975;132:316-335
12. Michel MF, Priem CC, Verbrugh HA, Goessens WHF: Staphylococcus aureus bacteremia in a Dutch Teaching Hospital. Infection 1985;13:267-271.
13. Nolan CM, Beaty HN: Staphylococcus aureus bacteremia. Am J Med 1976;60:495-500.
14. Poutrel B, Boutonnier A, Sutra L, Fournier JM: Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk. J Clin Microbiol 1988;26:38-40.
15. Raad II, Sabbagh MF: Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: A study of 55 cases and review. Clin Infect Dis 1992;14: 75-82.
16. Sheagren JN: Staphylococcus aureus: The persistent pathogen. N Engl J Med 1984;310:1368-1373.
17. Shinefield H: Staphylococcal infections of the newborn. In: Remington JS, Klein JO, Eds. Infectious Diseases of the Fetus and New Born Infant. 3rd Ed. Philadelphia: WB Saunders; 1990:866-892.
18. Simberkoff MS, Schiffman G, Katz LA, Spicehandler JR, Moldover NH, Rahal JJ Jr: Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients. J Lab Clin Med 1980;96:363-370.
19. Tam AY, Young C: The changing pattern of severe neonatal Staphylococcal infection. Aust Pediatr J 1988;24: 275-278.
20. Wilson NIL, DiPaolo M: Acute septic arthritis in infancy and childhood. 10 years' experience. J Bone Jt Surg Br Vol 1986;68B:584-587.
21. Luzar MA, Coles GA, Faller B, et al.: Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory dialysis. N Engl J Med 1990;322: 505-509.
22. Yu VL, Goetz A, Wagener M, et al.: Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. N Engl J Med 1986;315:91-96.
23. Centers for Disease Control: Mortality patterns - United States, 1988. MMWR 1991;40:493-502.
24. Foster TJ: Potential for vaccination against infections caused by Staphylococcus aureus. Vaccine 1991;9:221-226.
25. Fattom A, Schneerson R, Szu SC, et al.: Synthesis and immunologie properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990;58:2367-2374.
26. Fattom A, Lue C, Szu SC, et al.: Immune response in adult volunteers elicited by injection of the Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect Immun 1990;58:2309-2312.
27. Fattom A, Shiloach J, Bryla D, et al.: Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinnimidyl 3-(2-pyridyldithio) propionate. Infect Immun 1992;60:584-589.
28. Fattom A, Schneerson R, Watson DC, et al.: Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993;61:1023-1032.
29. Hochkeppel HK, Braun DG, Vischer W, et al.: Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol 1987;25:526-530.
30. Karakawa WW, Vann WF: Capsular polysaccharides of Staphylococcus aureus. In: Weinstein L, Fields BN, Eds. Seminars in Infectious Disease. Vol. IV. Bacterial vaccines. New York: Thieme-Stratton; 1982:285-293.
31. Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF: Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1988;56:1090-1095.
32. Karakawa WW, Fournier JM, Vann WF, Arbeit R, Schneerson R, Robbins JB: Methods for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol 1985;22:445-447.
33. Robbins JB, Schneerson R, Egan WB, Vann W, Liu DT: Virulence properties of bacterial capsular polysaccharides-unanswered questions. In: Smith H, Skehel JJ, Turner MJ, Eds. The Molecular Basis of Microbial Pathogenicity. Dahlen Konferenzen, October 22-26, 1980. Weinheim: Verlag Chemie GmbH; 1980:115-132.
34. Robbins JB, Schneerson R: Polysaccharide-protein conjugates. A new generation of vaccines. J Infect Dis 1990;161:821-832.
35. Sompolinsky D, Samra Z, Karakawa WW, Vann WF, Schneerson R, Malik Z: Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol 1985;22:828-834.
36. Fournier JM, Vann WF, Karakawa WW: Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect Immun 1984;45:87-93.
37. Moreau M, Richards JC, Fournier JM, Byrd RA, Karakawa WW, Vann WF: The structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carb Res 1990;201:285-297.
38. Cameron DM, Collier RJ: Exotoxin A of Pseudomonas aeruginosa: Substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity. J Bacteriol 1987;169:4967-4971.
39. Chaudhary VK, Jinno Y, Fitzgerald D, Pastan I: Pseudomonas exotoxin contains a specific sequence at the carboxylterminus that is required for cytotoxicity. Proc Natl Acad Sci USA 1990;87:308-312.
40. Fass R, van de Walle M, Shiloach A, Joslyn A, Kaufman J, Shiloach J: Use of high density cultures of Escherichia coli for high level production of recombinant Pseudomonas aeruginosa exotoxin A. Appl Microbiol Biotechnol 1991;36:65-69.
41. Lukac M, Pier GB, Collier RJ: Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue. Infect Immun 1988;56:3095-3098.
42. Pollack M, Young LS: Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest 1979;63:276-286.
43. Cryz SJ Jr, Sadoff JC, Furer E: Immunization with a Pseudomonas aeruginosa immunotype 5 0 polysaccharide-toxin A conjugate vaccine: Effect of a booster dose on antibody levels in humans. Infect Immun 1988;56: 1829-1830.
44. Schneerson R, Barrera O, Sutton A, Robbins JB: Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-376.
45. Schneerson R, Robbins JB, Parke JC Jr, et al.: Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986;52:519-528.
46. Pollack M, Callahan LT III, Taylor NS: Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: Evidence for in vivo toxin production during infections. Infect Immun 1976;14:942-947.
47. Iglewski B, Sadoff JD: Toxin inhibitors of protein synthesis: Production and purification of Pseudomonas aeruginosa exotoxin A. Methods Enzymol 1979;60:780-793.
48. Sutra L, Rainard P, Poutrel B: Phagocytosis of mastitis isolates of Staphylococcus aureus and expression of type 5 capsular polysaccharide are influenced by growth in the presence of milk. J Clin Microbiol 1990;28:2253-2258.
49. Schneerson R, Fattom A, Szu SC, et al.: Evaluation of monophosphoryl lipid A (MPL) as an adjuvant for human immunization: Enhancement of the serum antibody response in young mice to polysaccharide-protein conjugates by concurrent injection with MPL. J Immunol 1991;147:2136-2140.
50. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG: Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-465.
51. Sivonen A: Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carriage rates. J Infect 1981;3:266-272.
52. Takala AK, Eskola J, Leinonen M, et al.: Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children with immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-985.